incretin mimetics

Controlling blood glucose in type 2 diabetes remains challenging. All existing drugs have significant limitations and side effects, with some causing weight gain and thereby exacerbating the condition. This short review looks at new groups of drugs on the market and under development, and discusses their potential in the management of type 2 diabetes.

Keywords DPP-IV inhibitors, hypoglycaemia, incretin mimetics, obesity, thiazolidinediones, type 2 diabetes, weight loss drugs